4300 Hacienda Drive
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
Roche is the world leader in molecular and tissue diagnostics, and one of the leaders in clinical sequencing. As the innovation engine for Roche Diagnostics,Roche Molecular Solutions is translating cutting-edge science and innovation into clinical practice.
Visit our Career Blogs to see what our employees have to say about their life at Roche!
101 articles with Roche
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis
Shanghai Roche Pharmaceuticals Ltd. and Ascletis BioScience Co., Ltd. jointly announce that starting from 1st Dec 2018, Ascletis and Roche will expand their partnership in viral Hepatitis.
NewLink Genetics has announced, with the company restructuring and layoffs, they are refocusing on indoximod.
Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs.
Roche to showcase how labs are driving change across health networks to address PAMA and other challenges at AACC 2018 Clinical Lab Expo
Featured labs address challenges by streamlining processes, reducing costs and optimizing operations while ensuring delivery of care
Roche Keeping Busy After Q2 Report
7/31/2018Only a matter of days after Roche filed its second-quarter financial report, it’s had plenty of news to report.
For the first time, Merck’s Keytruda beat out Bristol-Myers Squibb’s Opdivo in sales.
Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of the year and a 20 percent increase in its core earnings per share (EPS).
Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study evaluating the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS)...
Promising Data for Celgene's Revlimid
7/24/2018Celgene announced data from its Phase III AUGMENT clinical trial that compared Revlimid (lenalidomide) and rituximab to placebo in relapsed/refractory follicular and marginal zone lymphoma.
Despite positive Phase III clinical trial data for Allergan’s age-related macular degeneration drug, investors weren’t as positive about it.
It was reported today that U.S.-based Merck & Co. will lower the price of some of its drug. It appears to be rippling through the industry, largely in an attempt to stay out of the way of Trump’s attack-tweets.
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
Boston-based PureTech Health inked a multi-year collaboration deal with Swiss-based Roche to advance PureTech’s milk-derived exosome platform technology for oral dosing of Roche’s antisense oligonucleotide platform.
Roche’s Tecentriq Sees Mixed Results in Interim Phase III Lung Cancer Analysis, Study to Continue
7/19/2018Roche’s Tecentriq, in combination with chemotherapy, hit its co-primary endpoint of progression-free survival in a Phase III trial for non-small cell lung cancer patients. But, the Swiss pharma giant said the combination has so far failed to achieve statistical significance in overall survival, a...
Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis
Elecsys® B·R·A·H·M·S PCT™ (procalcitonin) helps clinicians assess presence and severity of certain bacterial infections and patient response to antibiotics
President Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year. Other companies though have not followed suit and have gone through with price increases for their drugs.
Celgene Corporation announced that its Phase III IMpassion130 trial, sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS).
Shares of CTI BioPharma Corp. are down more than 15 percent in premarket trading this morning after the company announced its combination treatment for B-cell non-Hodgkin lymphoma failed to meet endpoints in a late-stage trial.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.